RIPK3 regulates microglial polarization through the TLR4/MyD88 pathway in neuropathic pain

Sihan E1, Qingbiao Song1, Zhaokun Zhang2

  • 1School of Anesthesiology, Shandong Second Medical University, Weifang, China.

Molecular Pain
|August 30, 2025
PubMed

Insights

Receptor-interacting protein kinase 3 (RIPK3) drives neuropathic pain by promoting M1 microglial polarization via the TLR4/MyD88 pathway. Inhibiting RIPK3 alleviates pain and shifts polarization to M2, offering a new therapeutic target.

Area of Science:

  • Neuroscience
  • Immunology
  • Cell Biology

Background:

  • Peripheral nerve injury triggers microglial activation and polarization in the spinal cord, contributing to neuropathic pain.
  • Necroptosis, a regulated form of cell death involving receptor-interacting protein kinases 3 (RIPK3), is implicated in neurological disorders.

Purpose of the Study:

  • To investigate the role of RIPK3 in regulating microglial polarization through the Toll-like receptor 4 (TLR4)/Myeloid differentiation primary response 88 (MyD88) signaling pathway in the context of neuropathic pain.

Main Methods:

  • A chronic constriction injury (CCI) mouse model was used to induce neuropathic pain.
  • In vitro studies utilized BV-2 microglia models treated with tumor necrosis factor-alpha (TNF-α)/Z-VAD.
  • RIPK3 inhibition was achieved using GSK'872, and TLR4 antagonism was employed.

Main Results:

  • CCI induced M1 microglial polarization and activated the TLR4/MyD88 pathway in the spinal cord.
  • TNF-α/Z-VAD treatment promoted M1 polarization via TLR4/MyD88 in microglia, an effect blocked by TLR4 antagonists.
  • GSK'872 administration inhibited the TLR4/MyD88 pathway, reduced M1 polarization, enhanced M2 polarization, and alleviated CCI-induced hyperalgesia.

Conclusions:

  • Necroptosis, mediated by RIPK3, is a critical cellular mechanism in peripheral nerve injury-induced neuropathic pain.
  • RIPK3 regulates microglial polarization through the TLR4/MyD88 signaling pathway.
  • Targeting RIPK3 offers a potential therapeutic strategy for neuropathic pain treatment and prevention.

Related Concept Videos

NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
7.8K
Analgesia and Pain Management01:25

Analgesia and Pain Management

Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
788
Nociception01:44

Nociception

Nociception—the ability to feel pain—is essential for an organism’s survival and overall well-being. Noxious stimuli such as piercing pain from a sharp object, heat from an open flame, or contact with corrosive chemicals are first detected by sensory receptors, called nociceptors, located on nerve endings. Nociceptors express ion channels that convert noxious stimuli into electrical signals. When these signals reach the brain via sensory neurons, they are perceived as pain.
29.4K